CN103347519B - 使用cns 7056(雷米马唑仑)镇静的给药方案 - Google Patents

使用cns 7056(雷米马唑仑)镇静的给药方案 Download PDF

Info

Publication number
CN103347519B
CN103347519B CN201180063667.0A CN201180063667A CN103347519B CN 103347519 B CN103347519 B CN 103347519B CN 201180063667 A CN201180063667 A CN 201180063667A CN 103347519 B CN103347519 B CN 103347519B
Authority
CN
China
Prior art keywords
cns
fentanyl
dose
purposes
cns7056
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CN201180063667.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103347519A (zh
Inventor
K·威廉奥古冈比伊
K·博克特
G·S·蒂尔布鲁克
H·威尔特希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan Humanwell Innovative Drug Research and Development Center Ltd Co
Original Assignee
Paion UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44907114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103347519(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Paion UK Ltd filed Critical Paion UK Ltd
Publication of CN103347519A publication Critical patent/CN103347519A/zh
Application granted granted Critical
Publication of CN103347519B publication Critical patent/CN103347519B/zh
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180063667.0A 2010-11-08 2011-11-07 使用cns 7056(雷米马唑仑)镇静的给药方案 Ceased CN103347519B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP10014366.8 2010-11-08
EP10014366 2010-11-08
EP10014784 2010-11-19
EP10014784.2 2010-11-19
EP10014819 2010-11-22
EP10014819.6 2010-11-22
EP10014972.3 2010-11-25
EP10014972A EP2450039A1 (en) 2010-11-08 2010-11-25 Dosing regimen for sedation with CNS 7056 (Remimazolam)
PCT/EP2011/005581 WO2012062439A1 (en) 2010-11-08 2011-11-07 Dosing regimen for sedation with cns 7056 (remimazolam)

Publications (2)

Publication Number Publication Date
CN103347519A CN103347519A (zh) 2013-10-09
CN103347519B true CN103347519B (zh) 2016-05-18

Family

ID=44907114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180063667.0A Ceased CN103347519B (zh) 2010-11-08 2011-11-07 使用cns 7056(雷米马唑仑)镇静的给药方案

Country Status (17)

Country Link
US (10) US9561236B2 (https=)
EP (3) EP2450039A1 (https=)
JP (1) JP6084571B2 (https=)
KR (1) KR102059399B1 (https=)
CN (1) CN103347519B (https=)
AU (1) AU2011328497B8 (https=)
DK (1) DK2637662T3 (https=)
EA (1) EA024926B1 (https=)
ES (1) ES2715179T3 (https=)
HR (1) HRP20190447T1 (https=)
HU (1) HUE044095T2 (https=)
LT (1) LT2637662T (https=)
PL (1) PL2637662T3 (https=)
PT (1) PT2637662T (https=)
RS (1) RS58577B1 (https=)
SI (1) SI2637662T1 (https=)
WO (1) WO2012062439A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108143733A (zh) * 2017-12-15 2018-06-12 宜昌人福药业有限责任公司 一种麻醉镇痛药物组合物及其制备方法

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2657347C (en) 2006-07-10 2014-11-18 Paion Uk Limited Short-acting benzodiazepine salts and their polymorphic forms
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168010A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of severe pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
NZ702063A (en) * 2012-05-22 2016-11-25 Paion Uk Ltd Compositions comprising short-acting benzodiazepines
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
UA116452C2 (uk) * 2012-08-31 2018-03-26 ПАЙОН ЮКей ЛІМІТЕД Режим дозування седативного засобу
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗炎症和脂质异常的组合物和方法
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN103232454A (zh) * 2013-05-05 2013-08-07 王元青 治疗精神疾病的药物
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
HUE047450T2 (hu) 2014-07-23 2020-04-28 Jiangsu Nhwaluokang Pharmaceutical Res And Development Co Ltd Új benzodiazepin származék és alkalmazása
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
WO2017013677A1 (en) 2015-07-18 2017-01-26 Neon Laboratories Limited Stable liquid injectable solution of midazolam and pentazocine
US10821087B2 (en) 2015-07-24 2020-11-03 Neon Laboratories Limited Stabilized injectable emulsion of Propofol and Ketamine
EP3442539B1 (en) * 2016-04-14 2025-04-09 Paion UK Limited Orally inhaled and nasal benzodiazepines
CN106407676A (zh) * 2016-09-12 2017-02-15 广东省农业科学院动物科学研究所 一种基于蒙特卡罗模拟的抗菌药物药效计算方法
EA202091927A1 (ru) * 2018-02-13 2020-12-07 Цзянсу Нхвалокан Фармасьютикал Рисерч Энд Дивелопмент Ко., Лтд. Гидрохлорид производного бензодиазепина и кристаллическая форма, способ их получения и применения
EP3714884A1 (en) * 2019-03-27 2020-09-30 Paion UK Limited Medical uses for benzodiazepines with a particular eeg pattern
CN112462015B (zh) * 2020-11-18 2022-07-12 海南倍特药业有限公司 一种氢溴酸瑞马唑仑细菌内毒素的检测方法
CN112402428B (zh) * 2020-11-26 2022-02-25 李依泽 瑞马唑仑在制备治疗阿片类药物诱发的术后痛觉过敏的药物中的应用
CN114903904B (zh) * 2021-02-08 2024-02-09 宜昌人福药业有限责任公司 瑞马唑仑药用盐和阿片样物质的注射用药物组合物
CN116270659A (zh) * 2023-01-13 2023-06-23 上海市胸科医院 瑞马唑仑在制备治疗、减缓或处理骨癌疼痛的产品中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007081A1 (en) * 2006-07-10 2008-01-17 Cenes Limited Short-acting benzodiazepine salts and their polymorphic forms

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520877A (en) 1967-10-02 1970-07-21 Hoffmann La Roche 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines
BR6915069D0 (pt) 1969-02-28 1973-08-16 Upjohn Co Compostos organicos e processo
GB1329464A (en) 1969-09-01 1973-09-12 Takeda Chemical Industries Ltd Process for producing benzodiazepine derivatives
DE2156472A1 (de) 1970-11-23 1972-05-31 Ciba-Geigy Ag, Basel (Schweiz) Verfahren zur Herstellung von neuen Diazepinderivaten
US3933794A (en) 1971-08-04 1976-01-20 The Upjohn Company 2-(2-Alkynylamino)-3H-1,4-benzodiazepines
FR2183716A1 (en) 1972-05-05 1973-12-21 Centre Etd Ind Pharma Substd-6-phenyl-4h-imidazo (1,2-a)-1,4-benzo diazepines - - tranquillisers anxiolytics,sedatives and muscle-relaxants
IE41197B1 (en) 1973-05-29 1979-11-07 Squibb & Sons Inc 4h-s-triazolo (4,3-a)(1,5)benzodiazepin-5-ones
CH608234A5 (en) 1974-08-30 1978-12-29 Crc Ricerca Chim Process for the preparation of lithium salts of 1,4-benzodiazepines
DE2900017A1 (de) 1978-01-10 1979-07-12 Clin Midy 3-alkoxycarbonyl-benzodiazepin- derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
MC1528A1 (fr) 1982-07-21 1984-04-13 Hoffmann La Roche Imidazobenzodiazepines
IT1165588B (it) 1983-03-23 1987-04-22 Medosan Ind Biochimi 1,4 benzodiazepine terapeuticamente attive
US4820834A (en) 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
US4724237A (en) 1984-06-26 1988-02-09 Merck & Co., Inc. 2-substituted-aminomethyl-1,4-benzodiazepines
CA1332410C (en) 1984-06-26 1994-10-11 Roger M. Freidinger Benzodiazepine analogs
US4755508A (en) 1984-06-26 1988-07-05 Merck & Co., Inc. Benzodiazepine analogs and use as antogonists of gastrin and cholecystokinin
DE3435973A1 (de) 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
EP0264797B1 (en) 1986-10-24 1996-01-10 Abbott Laboratories Benzodiazepines assay, tracers, immunogens and antibodies
WO1989010127A1 (en) 1988-04-29 1989-11-02 Baker Cummins Pharmaceuticals, Inc. Method of safely providing anesthesia or conscious sedation
US5019583A (en) 1989-02-15 1991-05-28 Glaxo Inc. N-phenyl-N-(4-piperidinyl)amides useful as analgesics
JPH0374328A (ja) 1989-08-04 1991-03-28 Warner Lambert Co 薬学的活性を有する中枢コレシストキニン拮抗剤
DK0450097T3 (da) 1989-10-20 1996-05-20 Otsuka Pharma Co Ltd Benzoheterocykliske forbindelser
CA2032427A1 (en) 1989-12-18 1991-06-19 Mark G. Bock Benzodiazepines analogs
IL96613A0 (en) 1989-12-18 1991-09-16 Merck & Co Inc Pharmaceutical compositions containing benzodiazepine analogs
US5324726A (en) 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
US5220017A (en) 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
US5185331A (en) 1991-05-14 1993-02-09 Merck & Co., Inc. Triazolobenzodiazepines
EP0523845A3 (en) 1991-06-14 1993-11-18 Merck & Co Inc New benzodiazepine analogs
GB9117852D0 (en) 1991-08-19 1991-10-09 Merck Sharp & Dohme Therapeutic agents
EP0638560A4 (en) 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
AU678503B2 (en) 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
US5834464A (en) 1994-11-18 1998-11-10 Merck & Co., Inc. Imidazolinobenzodiazepines
PT801651E (pt) 1995-01-06 2001-12-28 Hoffmann La Roche Hidroximetil-imidazodiazepinas e seus esteres
AU4382896A (en) 1995-02-02 1996-08-21 F. Hoffmann-La Roche Ag Acetylimidazobenzodiazepines
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
EP0907644A4 (en) 1996-06-28 2003-02-05 Merck & Co Inc PHARMACEUTICAL PREPARATION
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
EP0881235A1 (fr) 1997-05-26 1998-12-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux ylures de phosphore, leur préparation et leurs utilisations notamment en tant que bases fortes faiblement nucléophiles
US6440959B1 (en) 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
US7160880B1 (en) 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
US7806886B2 (en) 1999-06-03 2010-10-05 Medtronic Minimed, Inc. Apparatus and method for controlling insulin infusion with state variable feedback
EP1161949A1 (en) 2000-06-09 2001-12-12 Warner-Lambert Company Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
BR0306292A (pt) 2002-02-28 2004-08-24 Japan Tobacco Inc Composto de éster e uso medicinal do mesmo
HU226410B1 (en) 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
EP1718665B1 (en) 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
SI21850A (sl) 2004-07-28 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Soli olanzapina in njihova pretvorba v prosto bazo olanzapina
BRPI0517418A (pt) 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
CA2594940A1 (en) 2005-01-18 2006-07-27 Merck & Co., Inc. Cgrp receptor antagonists
MX2007009915A (es) 2005-02-15 2007-11-06 Elan Pharma Int Ltd Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada.
US20070040501A1 (en) 2005-08-18 2007-02-22 Aitken Bruce G Method for inhibiting oxygen and moisture degradation of a device and the resulting device
GB0613692D0 (en) 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts
CA2657347C (en) 2006-07-10 2014-11-18 Paion Uk Limited Short-acting benzodiazepine salts and their polymorphic forms
DK2155712T3 (en) 2007-05-22 2016-12-19 Chemocentryx Inc 3- (imidazolyl) pyrazolo [3,4-b] pyridines
WO2009145323A1 (ja) 2008-05-30 2009-12-03 日産化学工業株式会社 多環式化合物を用いるアルコールの酸化方法
JP2012505843A (ja) 2008-10-16 2012-03-08 パイオン ユーケー リミテッド 術後疼痛管理のための極性オピオイドの投与スキーム
JP4669584B2 (ja) 2009-03-30 2011-04-13 日本製紙株式会社 Ｎ−オキシル化合物の回収・再利用方法
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
RS54645B1 (sr) 2009-11-05 2016-08-31 Glaxosmithkline Llc Benzodiazepin kao inhibitor bromodomena
JP5635275B2 (ja) 2010-01-28 2014-12-03 日清紡ホールディングス株式会社 アルコールの酸化方法
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
CN102964349A (zh) 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途
JP5585597B2 (ja) 2012-01-27 2014-09-10 株式会社デンソー 車輪位置検出装置およびそれを備えたタイヤ空気圧検出装置
NZ702063A (en) 2012-05-22 2016-11-25 Paion Uk Ltd Compositions comprising short-acting benzodiazepines
UA116452C2 (uk) 2012-08-31 2018-03-26 ПАЙОН ЮКей ЛІМІТЕД Режим дозування седативного засобу
WO2014047903A1 (zh) 2012-09-28 2014-04-03 华为技术有限公司 信道状态信息进程处理方法、网络设备和用户设备
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007081A1 (en) * 2006-07-10 2008-01-17 Cenes Limited Short-acting benzodiazepine salts and their polymorphic forms

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dose-Finding Safety Study Evaluating CNS 7056 in Patients Undergoing;U.S. National Institutes of Health;《http://www.clinicaltrials.gov/ct2/show/nct00869440?term=cns+7056&rank=2》;20100930;第1－7页 *
fentanyl midazolam combination for endoscopy sedation is safe and effective;Cunningham;《GASTROENTEROLOGY》;19980415;第114卷(第4期);第1页 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108143733A (zh) * 2017-12-15 2018-06-12 宜昌人福药业有限责任公司 一种麻醉镇痛药物组合物及其制备方法
CN108143733B (zh) * 2017-12-15 2020-12-25 宜昌人福药业有限责任公司 一种麻醉镇痛药物组合物及其制备方法

Also Published As

Publication number Publication date
EA024926B1 (ru) 2016-11-30
SI2637662T1 (sl) 2019-05-31
US10342800B2 (en) 2019-07-09
DK2637662T3 (en) 2019-04-08
EP2637662B1 (en) 2019-01-09
US10722522B2 (en) 2020-07-28
JP2013541567A (ja) 2013-11-14
US10195210B2 (en) 2019-02-05
US20180042939A1 (en) 2018-02-15
AU2011328497A1 (en) 2013-04-18
US9827251B1 (en) 2017-11-28
US9561236B2 (en) 2017-02-07
US20140080815A1 (en) 2014-03-20
US12201637B2 (en) 2025-01-21
HRP20190447T1 (hr) 2019-05-03
KR102059399B1 (ko) 2019-12-26
EP2637662A1 (en) 2013-09-18
US10052334B2 (en) 2018-08-21
US20190111062A1 (en) 2019-04-18
ES2715179T3 (es) 2019-06-03
US20200316088A1 (en) 2020-10-08
PT2637662T (pt) 2019-03-25
AU2011328497B8 (en) 2015-04-16
EP2450039A1 (en) 2012-05-09
US20250360144A1 (en) 2025-11-27
US20180318316A1 (en) 2018-11-08
CN103347519A (zh) 2013-10-09
JP6084571B2 (ja) 2017-02-22
PL2637662T3 (pl) 2019-06-28
AU2011328497B2 (en) 2015-03-12
AU2011328497A8 (en) 2015-04-16
US20230346796A1 (en) 2023-11-02
LT2637662T (lt) 2019-04-10
KR20140000702A (ko) 2014-01-03
US9737547B2 (en) 2017-08-22
US20200171046A1 (en) 2020-06-04
EA201390672A1 (ru) 2013-11-29
RS58577B1 (sr) 2019-05-31
HUE044095T2 (hu) 2019-09-30
US20170112852A1 (en) 2017-04-27
WO2012062439A1 (en) 2012-05-18
EP3492080A1 (en) 2019-06-05

Similar Documents

Publication Publication Date Title
CN103347519B (zh) 使用cns 7056(雷米马唑仑)镇静的给药方案
JP4898073B2 (ja) 鼻内投与用フェンタニル組成物
CA2942638C (en) Method for noribogaine treatment of addiction in patients on methadone
EP1855657A2 (en) Dosage form containing oxycodone and naloxone
KR101437461B1 (ko) 부프레노르핀 및 날메펜을 함유하는 개량 약용 조성물
HK40008727A (en) Dosing regimen for sedation with cns 7056 (remimazolam)
HK1186122A (en) Dosing regimen for sedation with cns 7056 (remimazolam)
HK1186122B (en) Dosing regimen for sedation with cns 7056 (remimazolam)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220310

Address after: No. 666, hi tech Avenue, East Lake New Technology Development Zone, Wuhan, Hubei

Patentee after: Wuhan humanwell innovative drug R & D Center Co.,Ltd.

Address before: Britain Camb

Patentee before: PAION UK Ltd.

TR01 Transfer of patent right
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20181010

Decision number of declaring invalidation: 37405

Granted publication date: 20160518

IW01 Full invalidation of patent right